{"product_id":"anoro-ellipta","title":"Anoro Ellipta","description":"\u003cdiv class=\"flex-1 overflow-hidden @container\/thread translate-y-[2rem] -mt-[2rem] pb-[1.5rem]\"\u003e\r\n\u003cdiv class=\"flex h-full flex-col overflow-y-auto\"\u003e\r\n\u003cdiv class=\"flex flex-col text-sm md:pb-9\"\u003e\r\n\u003carticle class=\"w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]\" dir=\"auto\" data-testid=\"conversation-turn-63\" data-scroll-anchor=\"true\"\u003e\r\n\u003cdiv class=\"m-auto text-base py-[18px] px-6\"\u003e\r\n\u003cdiv class=\"mx-auto flex flex-1 text-base gap-4 md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\"\u003e\r\n\u003cdiv class=\"group\/conversation-turn relative flex w-full min-w-0 flex-col agent-turn @xs\/thread:px-0 @sm\/thread:px-1.5 @md\/thread:px-4\"\u003e\r\n\u003cdiv class=\"flex-col gap-1 md:gap-3\"\u003e\r\n\u003cdiv class=\"flex max-w-full flex-col flex-grow\"\u003e\r\n\u003cdiv class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+\u0026amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"492a9849-5c54-4c80-9834-5934994743e1\" data-message-model-slug=\"o3-mini\"\u003e\r\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\"\u003e\r\n\u003cdiv class=\"markdown prose w-full break-words dark:prose-invert light\"\u003e\r\n\u003ch3 data-start=\"234\" data-end=\"262\"\u003eWhat is Anoro Ellipta?\u003c\/h3\u003e\r\n\u003cp data-start=\"263\" data-end=\"476\"\u003e\u003cstrong data-start=\"263\" data-end=\"280\"\u003eAnoro Ellipta\u003c\/strong\u003e is a once‑daily inhalation medication approved for the long‑term maintenance treatment of chronic obstructive pulmonary disease (COPD). It is a fixed‑dose combination of two active ingredients:\u003c\/p\u003e\r\n\u003cul data-start=\"477\" data-end=\"741\"\u003e\r\n\u003cli data-start=\"477\" data-end=\"613\"\u003e\n\u003cstrong data-start=\"479\" data-end=\"495\"\u003eUmeclidinium\u003c\/strong\u003e, a long‑acting muscarinic antagonist (LAMA) that helps relax airway smooth muscle by blocking muscarinic receptors.\u003c\/li\u003e\r\n\u003cli data-start=\"614\" data-end=\"741\"\u003e\n\u003cstrong data-start=\"616\" data-end=\"630\"\u003eVilanterol\u003c\/strong\u003e, a long‑acting beta₂‑adrenergic agonist (LABA) that promotes bronchodilation by stimulating beta₂‑receptors.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"743\" data-end=\"855\"\u003eTogether, these agents improve lung function, reduce symptoms, and decrease the frequency of COPD exacerbations.\u003c\/p\u003e\r\n\u003cp data-start=\"857\" data-end=\"997\"\u003e\u003cem data-start=\"857\" data-end=\"997\"\u003eReference: U.S. Food and Drug Administration (FDA) prescribing information; ClinicalTrials.gov; American Thoracic Society (ATS) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"999\" data-end=\"1002\"\u003e\r\n\u003ch3 data-start=\"1004\" data-end=\"1061\"\u003eWhat are the other popular names for Anoro Ellipta?\u003c\/h3\u003e\r\n\u003cp data-start=\"1062\" data-end=\"1289\"\u003eAnoro Ellipta is primarily known by its brand name \u003cstrong data-start=\"1113\" data-end=\"1130\"\u003eAnoro Ellipta\u003c\/strong\u003e. It is also commonly referred to by its generic components, \u003cstrong data-start=\"1191\" data-end=\"1218\"\u003eumeclidinium\/vilanterol\u003c\/strong\u003e, or simply as the \"Anoro inhaler\" in clinical practice and literature.\u003c\/p\u003e\r\n\u003cp data-start=\"1291\" data-end=\"1359\"\u003e\u003cem data-start=\"1291\" data-end=\"1359\"\u003eReference: U.S. FDA; National Institutes of Health (NIH) resources\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1361\" data-end=\"1364\"\u003e\r\n\u003ch3 data-start=\"1366\" data-end=\"1421\"\u003eWhat is the drug classification of Anoro Ellipta?\u003c\/h3\u003e\r\n\u003cp data-start=\"1422\" data-end=\"1720\"\u003eAnoro Ellipta is classified as a \u003cstrong data-start=\"1455\" data-end=\"1486\"\u003ecombination inhaled therapy\u003c\/strong\u003e for respiratory diseases, specifically within the category of \u003cstrong data-start=\"1549\" data-end=\"1589\"\u003edual bronchodilator therapy for COPD\u003c\/strong\u003e. It belongs to the LAMA\/LABA class, which is widely recommended for improving airflow and reducing exacerbations in COPD patients.\u003c\/p\u003e\r\n\u003cp data-start=\"1722\" data-end=\"1850\"\u003e\u003cem data-start=\"1722\" data-end=\"1850\"\u003eReference: U.S. FDA; Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; American Thoracic Society (ATS)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1852\" data-end=\"1855\"\u003e\r\n\u003ch3 data-start=\"1857\" data-end=\"1907\"\u003eWhat is the mode of action of Anoro Ellipta?\u003c\/h3\u003e\r\n\u003cp data-start=\"1908\" data-end=\"1957\"\u003eAnoro Ellipta employs a dual mechanism of action:\u003c\/p\u003e\r\n\u003cul data-start=\"1958\" data-end=\"2239\"\u003e\r\n\u003cli data-start=\"1958\" data-end=\"2093\"\u003e\n\u003cstrong data-start=\"1960\" data-end=\"1984\"\u003eUmeclidinium (LAMA):\u003c\/strong\u003e Inhibits muscarinic receptors in the airway smooth muscle, reducing bronchoconstriction and mucus secretion.\u003c\/li\u003e\r\n\u003cli data-start=\"2094\" data-end=\"2236\"\u003e\n\u003cstrong data-start=\"2096\" data-end=\"2118\"\u003eVilanterol (LABA):\u003c\/strong\u003e Stimulates beta₂‑adrenergic receptors, leading to relaxation of airway smooth muscles and subsequent bronchodilation.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2240\" data-end=\"2378\"\u003eThe synergistic effects of these two agents improve lung ventilation, increase forced expiratory volume, and help alleviate COPD symptoms.\u003c\/p\u003e\r\n\u003cp data-start=\"2380\" data-end=\"2485\"\u003e\u003cem data-start=\"2380\" data-end=\"2485\"\u003eReference: New England Journal of Medicine (NEJM) publications on dual bronchodilator therapy; U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2487\" data-end=\"2490\"\u003e\r\n\u003ch3 data-start=\"2492\" data-end=\"2524\"\u003eHow is Anoro Ellipta used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2525\" data-end=\"2833\"\u003eAnoro Ellipta is used as a \u003cstrong data-start=\"2552\" data-end=\"2575\"\u003emaintenance therapy\u003c\/strong\u003e for COPD in adult patients. It is prescribed for those who require long‑term bronchodilation and improved lung function, particularly in patients with moderate to severe COPD. It is not intended for the relief of acute bronchospasm or for asthma management.\u003c\/p\u003e\r\n\u003cp data-start=\"2835\" data-end=\"2900\"\u003e\u003cem data-start=\"2835\" data-end=\"2900\"\u003eReference: American Thoracic Society (ATS) guidelines; U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2902\" data-end=\"2905\"\u003e\r\n\u003ch3 data-start=\"2907\" data-end=\"2981\"\u003eWhat is the recommended dosage and administration for Anoro Ellipta?\u003c\/h3\u003e\r\n\u003cul data-start=\"2982\" data-end=\"3502\"\u003e\r\n\u003cli data-start=\"2982\" data-end=\"3234\"\u003e\n\u003cstrong data-start=\"2984\" data-end=\"2995\"\u003eDosage:\u003c\/strong\u003e The standard dose is \u003cstrong data-start=\"3017\" data-end=\"3046\"\u003eone inhalation once daily\u003c\/strong\u003e from the Ellipta device. Each inhalation typically delivers a fixed dose of approximately 62.5 mcg of umeclidinium and 25 mcg of vilanterol (doses may vary based on regional approvals).\u003c\/li\u003e\r\n\u003cli data-start=\"3235\" data-end=\"3502\"\u003e\n\u003cstrong data-start=\"3237\" data-end=\"3256\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"3261\" data-end=\"3502\"\u003e\r\n\u003cli data-start=\"3261\" data-end=\"3309\"\u003eInhale once daily at the same time each day.\u003c\/li\u003e\r\n\u003cli data-start=\"3312\" data-end=\"3499\"\u003eRinse your mouth after inhalation to reduce the risk of oral thrush (a potential side effect of inhaled corticosteroids used in similar devices, though not applicable to Anoro Ellipta).\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3503\" data-end=\"3596\"\u003e\u003cem data-start=\"3503\" data-end=\"3596\"\u003eReference: U.S. FDA prescribing information; ClinicalTrials.gov (e.g., NCT01691508 studies)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3598\" data-end=\"3601\"\u003e\r\n\u003ch3 data-start=\"3603\" data-end=\"3669\"\u003eWhat prescribing information is important for Anoro Ellipta?\u003c\/h3\u003e\r\n\u003cul data-start=\"3670\" data-end=\"4280\"\u003e\r\n\u003cli data-start=\"3670\" data-end=\"3791\"\u003e\n\u003cstrong data-start=\"3672\" data-end=\"3688\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3693\" data-end=\"3791\"\u003e\r\n\u003cli data-start=\"3693\" data-end=\"3791\"\u003eIndicated for the long‑term maintenance treatment of airflow limitation in patients with COPD.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3792\" data-end=\"4051\"\u003e\n\u003cstrong data-start=\"3794\" data-end=\"3816\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3821\" data-end=\"4051\"\u003e\r\n\u003cli data-start=\"3821\" data-end=\"3936\"\u003eNot for use in patients with acute episodes of bronchospasm or for the immediate relief of acute COPD symptoms.\u003c\/li\u003e\r\n\u003cli data-start=\"3939\" data-end=\"4051\"\u003eContraindicated in patients with known hypersensitivity to umeclidinium, vilanterol, or any of the excipients.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4052\" data-end=\"4280\"\u003e\n\u003cstrong data-start=\"4054\" data-end=\"4069\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"4074\" data-end=\"4280\"\u003e\r\n\u003cli data-start=\"4074\" data-end=\"4153\"\u003ePatients should be regularly monitored for symptom control and lung function.\u003c\/li\u003e\r\n\u003cli data-start=\"4156\" data-end=\"4280\"\u003ePeriodic assessment of heart rate and blood pressure is advised, as LABAs can occasionally affect cardiovascular function.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4282\" data-end=\"4373\"\u003e\u003cem data-start=\"4282\" data-end=\"4373\"\u003eReference: U.S. FDA; American Thoracic Society (ATS); National Institutes of Health (NIH)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4375\" data-end=\"4378\"\u003e\r\n\u003ch3 data-start=\"4380\" data-end=\"4468\"\u003eWhat safety information, warnings, and cautions are associated with Anoro Ellipta?\u003c\/h3\u003e\r\n\u003cul data-start=\"4469\" data-end=\"5129\"\u003e\r\n\u003cli data-start=\"4469\" data-end=\"4552\"\u003e\n\u003cstrong data-start=\"4471\" data-end=\"4495\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4500\" data-end=\"4552\"\u003e\r\n\u003cli data-start=\"4500\" data-end=\"4552\"\u003eDry mouth, cough, headache, and throat irritation.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4553\" data-end=\"4923\"\u003e\n\u003cstrong data-start=\"4555\" data-end=\"4579\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4584\" data-end=\"4923\"\u003e\r\n\u003cli data-start=\"4584\" data-end=\"4708\"\u003e\n\u003cstrong data-start=\"4586\" data-end=\"4613\"\u003eCardiovascular Effects:\u003c\/strong\u003e Although generally well-tolerated, LABAs may occasionally cause tachycardia or palpitations.\u003c\/li\u003e\r\n\u003cli data-start=\"4711\" data-end=\"4817\"\u003e\n\u003cstrong data-start=\"4713\" data-end=\"4742\"\u003eParadoxical Bronchospasm:\u003c\/strong\u003e Discontinue use immediately if worsening of respiratory symptoms occurs.\u003c\/li\u003e\r\n\u003cli data-start=\"4820\" data-end=\"4923\"\u003e\n\u003cstrong data-start=\"4822\" data-end=\"4840\"\u003eLocal Effects:\u003c\/strong\u003e Patients should rinse their mouth after use to reduce the risk of oral irritation.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4924\" data-end=\"5129\"\u003e\n\u003cstrong data-start=\"4926\" data-end=\"4947\"\u003eSpecial Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4952\" data-end=\"5129\"\u003e\r\n\u003cli data-start=\"4952\" data-end=\"5018\"\u003eUse with caution in patients with severe cardiovascular disease.\u003c\/li\u003e\r\n\u003cli data-start=\"5021\" data-end=\"5129\"\u003eNot recommended for acute symptom relief; a separate short-acting bronchodilator should be used if needed.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5131\" data-end=\"5259\"\u003e\u003cem data-start=\"5131\" data-end=\"5259\"\u003eReference: U.S. FDA; Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; American Thoracic Society (ATS)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5261\" data-end=\"5264\"\u003e\r\n\u003ch3 data-start=\"5266\" data-end=\"5335\"\u003eWhat drug interactions should be considered with Anoro Ellipta?\u003c\/h3\u003e\r\n\u003cul data-start=\"5336\" data-end=\"5830\"\u003e\r\n\u003cli data-start=\"5336\" data-end=\"5537\"\u003e\n\u003cstrong data-start=\"5338\" data-end=\"5364\"\u003eOther Bronchodilators:\u003c\/strong\u003e\r\n\u003cul data-start=\"5369\" data-end=\"5537\"\u003e\r\n\u003cli data-start=\"5369\" data-end=\"5537\"\u003eConcurrent use with other long‑acting bronchodilators may increase the risk of adverse cardiovascular effects; therapy should be managed by a healthcare professional.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5538\" data-end=\"5656\"\u003e\n\u003cstrong data-start=\"5540\" data-end=\"5558\"\u003eBeta‑Blockers:\u003c\/strong\u003e\r\n\u003cul data-start=\"5563\" data-end=\"5656\"\u003e\r\n\u003cli data-start=\"5563\" data-end=\"5656\"\u003eNon‑selective beta‑blockers can potentially reduce the bronchodilator effect of vilanterol.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5657\" data-end=\"5830\"\u003e\n\u003cstrong data-start=\"5659\" data-end=\"5681\"\u003eCYP3A4 Inhibitors:\u003c\/strong\u003e\r\n\u003cul data-start=\"5686\" data-end=\"5830\"\u003e\r\n\u003cli data-start=\"5686\" data-end=\"5830\"\u003eAlthough the systemic exposure is low, caution is advised when using strong CYP3A4 inhibitors, as they may alter the metabolism of vilanterol.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5832\" data-end=\"5918\"\u003e\u003cem data-start=\"5832\" data-end=\"5918\"\u003eReference: U.S. FDA prescribing information; Clinical Pharmacology Reviews on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5920\" data-end=\"5923\"\u003e\r\n\u003ch3 data-start=\"5925\" data-end=\"6022\"\u003eWhere can I find additional clinical evidence and detailed information about Anoro Ellipta?\u003c\/h3\u003e\r\n\u003cp data-start=\"6023\" data-end=\"6110\"\u003eFor more detailed clinical data, dosing guidelines, and safety information, refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"6111\" data-end=\"6494\"\u003e\r\n\u003cli data-start=\"6111\" data-end=\"6199\"\u003e\n\u003cstrong data-start=\"6113\" data-end=\"6165\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6166\" data-end=\"6197\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6200\" data-end=\"6289\"\u003e\n\u003cstrong data-start=\"6202\" data-end=\"6225\"\u003eClinicalTrials.gov:\u003c\/strong\u003e Search for trials involving Anoro Ellipta (e.g., NCT01691508)\u003c\/li\u003e\r\n\u003cli data-start=\"6290\" data-end=\"6408\"\u003e\n\u003cstrong data-start=\"6292\" data-end=\"6369\"\u003eGlobal Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines:\u003c\/strong\u003e \u003ca href=\"https:\/\/goldcopd.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6370\" data-end=\"6406\"\u003eGOLD Report\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6409\" data-end=\"6494\"\u003e\n\u003cstrong data-start=\"6411\" data-end=\"6457\"\u003eAmerican Thoracic Society (ATS) Resources:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.thoracic.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6458\" data-end=\"6494\"\u003eATS.org\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"6496\" data-end=\"6499\"\u003e\r\n\u003ch3 data-start=\"6501\" data-end=\"6521\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"6522\" data-end=\"7133\"\u003e\u003cstrong data-start=\"6522\" data-end=\"6539\"\u003eAnoro Ellipta\u003c\/strong\u003e provides a convenient, once‑daily dual bronchodilator therapy for patients with COPD. By combining the complementary actions of umeclidinium (a LAMA) and vilanterol (a LABA), it enhances airflow, reduces symptoms, and improves overall lung function. Due to its specific dosing regimen and potential for interactions with other medications (such as beta‑blockers and CYP3A4 inhibitors), it must be used as directed and under the guidance of a healthcare provider. Patients should be well‑instructed on proper inhaler technique to maximize the therapeutic benefits while minimizing side effects.\u003c\/p\u003e\r\n\u003cp data-start=\"7135\" data-end=\"7359\"\u003e\u003cem data-start=\"7135\" data-end=\"7359\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/article\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"EZ Chemist","offers":[{"title":"30 Doses \/ 62.5\/25mcg","offer_id":51735706304795,"sku":"Anoro Ellipta-30 Doses-62.5\/25mcg","price":190.74,"currency_code":"USD","in_stock":true},{"title":"60 Doses \/ 62.5\/25mcg","offer_id":51735706337563,"sku":"Anoro Ellipta-60 Doses-62.5\/25mcg","price":322.74,"currency_code":"USD","in_stock":true},{"title":"90 Doses \/ 62.5\/25mcg","offer_id":51735706370331,"sku":"Anoro Ellipta-90 Doses-62.5\/25mcg","price":413.4,"currency_code":"USD","in_stock":true}],"url":"https:\/\/ezchemist.com\/products\/anoro-ellipta","provider":"EZ Chemist","version":"1.0","type":"link"}